Targeting the
Impossible
TAREXIS is a biotech company advancing innovative therapeutics through novel target discovery for patients with limited treatment options.
Platform
Proprietary Discovery Platforms
Two integrated platforms systematically narrow the field to high-confidence targets and pre-validate their clinical performance before IND-enabling studies begin.
01 Tx-Finder™
Autonomous multi-omics Analytics Engine
- Auto-prioritize best targets from 10,000+ candidates
- Multi-omics integration & algorithmic scoring
- Multi-dimensional: druggability + market attractiveness
- Surface expression, receptor identity, safety profile
4-Step Candidate Filtering Process
Step 1
Overexpressed protein (DEP)
- Overexpression (Tier-based selection)
Step 2
Druggability
- Membrane expression
- Receptor identity
- Antigen protein structure
Step 3
Toxicity prediction (Toxicity)
- Normal-tissue expression
- Immune-cell expression
Step 4
Market attractiveness (Novelty)
- Development status
- Indication-expansion potential
02 Tx-Verifier™
Patient-Derived Organoid Based Validation Platform
- PDOs from patient-derived clinical samples
- Fail-gate strategy: eliminate poor candidates early
- Responder profiling & classification
- Patient-derived organoid xenograft (PDOX) model
Pipeline
| Program | Class | Indication | Modality | Stage | Partner |
|---|---|---|---|---|---|
| TX-101 | FIC | LSCC · Metastatic Solid Tumors | ADC | Discovery | Undisclosed |
| TX-102 | FIC | Solid Tumors | ADC | Discovery | Undisclosed |
| TX-103 | FIC | Solid Tumors | ADC | Discovery | Undisclosed |
| TX-104 | FIC | Solid Tumors | ADC | Discovery | Undisclosed |
| TX-201 | FIC | CRC | ADC | Discovery | — |
| TX-301 | FIC | PDAC | ADC | Discovery | — |
LSCC: Lung Squamous Cell Carcinoma · CRC: Colorectal Cancer · PDAC: Pancreatic Ductal Adenocarcinoma
Contact
Email
tarexis@tarexis.com
Location
Room 512, 34, Sangwon 12-gil, Seongdong-gu, Seoul, Republic of KoreaInquiry
Tell us about your interest and we'll be in touch.